BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15897574)

  • 1. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
    Dennis JL; Hvidsten TR; Wit EC; Komorowski J; Bell AK; Downie I; Mooney J; Verbeke C; Bellamy C; Keith WN; Oien KA
    Clin Cancer Res; 2005 May; 11(10):3766-72. PubMed ID: 15897574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
    Horlings HM; van Laar RK; Kerst JM; Helgason HH; Wesseling J; van der Hoeven JJ; Warmoes MO; Floore A; Witteveen A; Lahti-Domenici J; Glas AM; Van't Veer LJ; de Jong D
    J Clin Oncol; 2008 Sep; 26(27):4435-41. PubMed ID: 18802156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin.
    Dennis JL; Vass JK; Wit EC; Keith WN; Oien KA
    Cancer Res; 2002 Nov; 62(21):5999-6005. PubMed ID: 12414618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic strategies for unknown primary cancer.
    Varadhachary GR; Abbruzzese JL; Lenzi R
    Cancer; 2004 May; 100(9):1776-85. PubMed ID: 15112256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
    Park SY; Kim BH; Kim JH; Lee S; Kang GH
    Arch Pathol Lab Med; 2007 Oct; 131(10):1561-7. PubMed ID: 17922593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin.
    Azoulay S; Adem C; Pelletier FL; Barete S; Francès C; Capron F
    J Cutan Pathol; 2005 Sep; 32(8):561-6. PubMed ID: 16115055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic yield of tumor markers in cancer of unknown primary site.
    Parvez T; Ibraheim MI
    J Coll Physicians Surg Pak; 2006 Feb; 16(2):154-6. PubMed ID: 16499817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical identification of carcinomas of unknown primary in serous effusions.
    Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A
    Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.
    DeYoung BR; Wick MR
    Semin Diagn Pathol; 2000 Aug; 17(3):184-93. PubMed ID: 10968704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site.
    Brown RW; Campagna LB; Dunn JK; Cagle PT
    Am J Clin Pathol; 1997 Jan; 107(1):12-9. PubMed ID: 8980361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying tumor origin using a gene expression-based classification map.
    Buckhaults P; Zhang Z; Chen YC; Wang TL; St Croix B; Saha S; Bardelli A; Morin PJ; Polyak K; Hruban RH; Velculescu VE; Shih IeM
    Cancer Res; 2003 Jul; 63(14):4144-9. PubMed ID: 12874019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An immunohistological study of metastatic adenocarcinoma of the lymph node: is it useful in diagnosing a primary tumor?].
    Hamaya K; Doi K; Yoshizawa S; Motoi M
    Gan No Rinsho; 1988 Nov; 34(14):1956-60. PubMed ID: 2462648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunohistochemical flow chart to differentiate between primary adenocarcinoma and the most frequent extragynecological metastases in the ovary].
    Pires Y; Andrade L; Cuello M; Chuaqui R
    Rev Med Chil; 2002 Nov; 130(11):1232-40. PubMed ID: 12587505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; McMillan A
    Cancer; 2006 Jun; 106(12):2592-7. PubMed ID: 16688775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Unknown primary tumour--diagnostic strategies and treatment].
    Møller AK; Gundgaard MG; Petersen BL; Daugaard G
    Ugeskr Laeger; 2008 Nov; 170(48):3946-9. PubMed ID: 19087733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CUP syndrome: are there advances?].
    Moll R
    Verh Dtsch Ges Pathol; 2005; 89():125-36. PubMed ID: 18035682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.